Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Grebely

Showing results (341-350 of 368) with videos related to

Pageof 37
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 14, 2019
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International StudyAndreea A Artenie, Evan B Cunningham, Gregory J Dore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 3, 2019
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist TherapyEvan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2020
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject DrugsEvan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
BMC Infectious Diseases|June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyEvan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
The Journal of Infectious Diseases|August 31, 2016
Historical Trends in the Hepatitis C Virus Epidemics in North America and AustraliaChaturaka Rodrigo, Auda A Eltahla, Rowena A Bull, et al.
AIDS (London, England)|July 19, 2023
Reinfection incidence and risk among people treated for recent hepatitis C virus infectionMarianne Martinello, Joanne M Carson, Marc Van Der Valk, et al.
Viruses|July 27, 2022
A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage StudyAnna Conway, Heather Valerio, Maryam Alavi, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infectionJason Grebely, Kimberly Page, Rachel Sacks-Davis, et al.
Annals of Internal Medicine|August 8, 2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort StudyJason Grebely, Gregory J Dore, Frederick L Altice, et al.
The International Journal on Drug Policy|May 25, 2024
Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugsTimothy R Broady, Heather Valerio, Maryam Alavi, et al.
Pageof 37

Showing results (341-350 of 368) with videos related to

Sort By:
Pageof 37
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 14, 2019
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International StudyAndreea A Artenie, Evan B Cunningham, Gregory J Dore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 3, 2019
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist TherapyEvan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2020
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject DrugsEvan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
BMC Infectious Diseases|June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyEvan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
The Journal of Infectious Diseases|August 31, 2016
Historical Trends in the Hepatitis C Virus Epidemics in North America and AustraliaChaturaka Rodrigo, Auda A Eltahla, Rowena A Bull, et al.
AIDS (London, England)|July 19, 2023
Reinfection incidence and risk among people treated for recent hepatitis C virus infectionMarianne Martinello, Joanne M Carson, Marc Van Der Valk, et al.
Viruses|July 27, 2022
A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage StudyAnna Conway, Heather Valerio, Maryam Alavi, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infectionJason Grebely, Kimberly Page, Rachel Sacks-Davis, et al.
Annals of Internal Medicine|August 8, 2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort StudyJason Grebely, Gregory J Dore, Frederick L Altice, et al.
The International Journal on Drug Policy|May 25, 2024
Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugsTimothy R Broady, Heather Valerio, Maryam Alavi, et al.
Pageof 37